Ritlecitinib
- Generic Name
- Ritlecitinib
- Brand Names
- Litfulo
- Drug Type
- Small Molecule
- Chemical Formula
- C15H19N5O
- CAS Number
- 1792180-81-4
- Unique Ingredient Identifier
- 2OYE00PC25
- Background
Ritlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. In June 2023, it was approved by the FDA for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It was further approved by the EMA in September 2023. Ritlecit...
- Indication
Ritlecitinib is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. It is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
- Associated Conditions
- Severe Alopecia Areata (AA)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.